ENABLE 2 Pivotal CML Design Disclosed

Company Enliven Therapeutics Event Type Regulatory design alignment (company-reported) Modality Small molecule (ATP-competitive BCR::ABL1 inhibitor) Asset Relcobatinib (ELVN-001) Target BCR::ABL1 Disease Area Chronic myeloid leukemia (previously treated) Summary Enliven reported FDA alignment on the design of ENABLE-2, a planned randomized Phase 3 trial of relcobatinib…